Sangamo Therapeutics Investor Relations Material
Latest events
Q2 2025
Sangamo Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sangamo Therapeutics Inc
Access all reports
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in therapeutic genome editing. The company's lead program is focused on treating inherited blood disorder beta-thalassemia and sickle cell disease by ex vivo genome editing in hematopoietic stem and progenitor cells from adult patients. It is also focusing on genome editing for HIV/AIDS; hemophilia; Huntington's disease; LCA6; other rare and infectious diseases; cancer and degenerative conditions. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Key slides for Sangamo Therapeutics Inc
Q2 2025
Sangamo Therapeutics Inc
Q2 2025
Sangamo Therapeutics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SGMO
Country
🇺🇸 United States